Flow cytometry assays confirmed that the Ab bispecific construct was able to target both Her2-positive human breast cancer SKBR3 cells in combination with CD3-positive human peripheral blood mononuclear cells, which served as the effector cells.199 Therefore, the CD3xHer2 bispecific Ab had an effect on T cell-mediated lysis of Her2-positive breast cancer cells. This evidence concerns the gene ERBB2 and breast carcinoma.